Trending NewsTrending NewsNYSE:NVO Novo Nordisk A/S (NVO) Stock Price, News & Analysis $45.15 -1.45 (-3.11%) Closing price 03:59 PM EasternExtended Trading$45.24 +0.08 (+0.18%) As of 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Novo Nordisk A/S Stock (NYSE:NVO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Novo Nordisk A/S alerts:Sign Up Key Stats Today's Range$45.15▼$45.9150-Day Range$44.16▼$51.5652-Week Range$35.12▼$64.16Volume8.86 million shsAverage Volume17.31 million shsMarket Capitalization$201.60 billionP/E Ratio11.04Dividend Yield1.82%Price Target$64.94Consensus RatingHold Company Overview Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support. The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments. Novo Nordisk has been a major commercial and scientific driver of GLP-1 receptor agonists, marketed under well-known brand names for glucose control and weight management. In addition to diabetes and obesity medicines, the company supplies treatments for haemophilia and other rare bleeding disorders, as well as growth disorders and hormone replacement therapies. Its offerings combine pharmaceuticals with delivery devices and patient services aimed at improving adherence and outcomes. Research and development are central to Novo Nordisk’s strategy, with continued investment in next-generation medicines for metabolic, cardiovascular and rare diseases. The company operates global manufacturing and distribution networks and markets its products broadly, with significant commercial operations in the United States, Europe and other international markets. Novo Nordisk also engages in partnerships and licensing arrangements with academic institutions, biotechnology firms and healthcare organizations to support innovation and expand access to therapies. Leadership is focused on long-term innovation and patient-centric care; the company is led by President and CEO Lars Fruergaard Jørgensen. Novo Nordisk positions itself as a specialist pharmaceutical company with a mission to improve the lives of people with chronic conditions through medical innovation, comprehensive treatment solutions and support services for patients and healthcare providers.AI Generated. May Contain Errors. Read More Novo Nordisk A/S Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks82nd Percentile Overall ScoreNVO MarketRank™: Novo Nordisk A/S scored higher than 82% of companies evaluated by MarketBeat, and ranked 92nd out of 906 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingHold Consensus RatingNovo Nordisk A/S has received a consensus rating of Hold. The company's average rating score is 2.16, and is based on no strong buy ratings, 4 buy ratings, 14 hold ratings, and 1 sell rating.Upside PotentialNovo Nordisk A/S has a consensus price target of $64.94, representing about 42.7% upside from its current price of $45.51.Amount of Analyst CoverageNovo Nordisk A/S has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Novo Nordisk A/S's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth-0.87% Earnings GrowthEarnings for Novo Nordisk A/S are expected to decrease by -0.87% in the coming year, from $3.45 to $3.42 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Novo Nordisk A/S is 11.11, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.21.Price to Earnings Ratio vs. SectorThe P/E ratio of Novo Nordisk A/S is 11.11, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 271.49.Price to Earnings Growth RatioNovo Nordisk A/S has a PEG Ratio of 1.56. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioNovo Nordisk A/S has a P/B Ratio of 6.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Novo Nordisk A/S's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.76% of the float of Novo Nordisk A/S has been sold short.Short Interest Ratio / Days to CoverNovo Nordisk A/S has a short interest ratio ("days to cover") of 2.18, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Novo Nordisk A/S has recently increased by 14.97%, indicating that investor sentiment is decreasing significantly. Dividend2.5 / 5Dividend StrengthModerate Dividend YieldNovo Nordisk A/S pays a meaningful dividend of 1.75%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthNovo Nordisk A/S does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Novo Nordisk A/S is 20.05%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Novo Nordisk A/S will have a dividend payout ratio of 23.98% next year. This indicates that Novo Nordisk A/S will be able to sustain or increase its dividend.Read more about Novo Nordisk A/S's dividend. News and Social Media3.5 / 5News Sentiment0.60 News SentimentNovo Nordisk A/S has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 29 news articles for Novo Nordisk A/S this week, compared to 8 articles on an average week.Search Interest75 people have searched for NVO on MarketBeat in the last 30 days. This is an increase of 15% compared to the previous 30 days.MarketBeat Follows27 people have added Novo Nordisk A/S to their MarketBeat watchlist in the last 30 days. This is an increase of 42% compared to the previous 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Novo Nordisk A/S insiders have not sold or bought any company stock.Percentage Held by Insiders0.07% of the stock of Novo Nordisk A/S is held by insiders.Percentage Held by Institutions11.54% of the stock of Novo Nordisk A/S is held by institutions.Read more about Novo Nordisk A/S's insider trading history. Receive NVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novo Nordisk A/S and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NVO Stock News HeadlinesGLP1 Drugs Work for Kids, Says Novo Nordisk. They Could Be Another Huge Market.1 hour ago | msn.comWegovy for overweight young children: Novo Nordisk’s obesity drug shows effectiveness1 hour ago | msn.comWashington Can't Stop BorrowingAmerica's national debt just hit $40.07 trillion, growing by billions each day with no plan to slow it down. Preserve Gold, trusted by 800 plus five-star reviewers, offers a free 2026 Gold and Silver Kit showing how to move part of an eligible 401k or IRA into physical metals tax and penalty free. Qualified purchases or rollovers can also unlock up to $20,000 in cashback through September 31, 2026.September 8 at 1:00 AM | Preserve Gold (Ad)Why CEO of Wegovy maker Novo Nordisk isn't sold yet on the peptide crazeSeptember 8 at 9:12 AM | msn.comNovo Nordisk faces fresh setback as it halts two heart drug trialsSeptember 8 at 9:12 AM | msn.comNovo Nordisk: STEP Young Wins, But Heart Trials Just Got Halted (Rating Downgrade)September 8 at 9:12 AM | seekingalpha.comEli Lilly vs. Novo Nordisk: One Has 39% Upside. I'm Picking the Other.September 8 at 9:12 AM | barchart.comHims & Hers’ Revenue Beat Came With a Profitability Problem (NVO)Hims & Hers topped Q2 revenue estimates and raised guidance, but missed EPS forecasts, posted a wider net loss, and faces an FTC lawsuit, leaving Wall Street cautious with a Hold rating.August 12, 2026 | marketbeat.comSee More Headlines NVO Stock Analysis - Frequently Asked Questions How have NVO shares performed this year? Novo Nordisk A/S's stock was trading at $50.88 at the beginning of 2026. Since then, NVO stock has decreased by 10.6% and is now trading at $45.5050. How were Novo Nordisk A/S's earnings last quarter? Novo Nordisk A/S (NYSE:NVO) released its earnings results on Tuesday, June, 30th. The company reported $0.94 earnings per share for the quarter. The company earned $11.98 billion during the quarter. Novo Nordisk A/S had a net margin of 35.36% and a trailing twelve-month return on equity of 61.20%. When did Novo Nordisk A/S's stock split? Novo Nordisk A/S shares split before market open on Wednesday, September 20th 2023.The 2-1 split was announced on Wednesday, September 20th 2023. The newly issued shares were distributed to shareholders after the closing bell on Wednesday, September 20th 2023. An investor that had 100 shares of stock prior to the split would have 200 shares after the split. Does Novo Nordisk A/S have any subsidiaries? The following companies are subsidiaries of Novo Nordisk A/S: Dicerna Pharmaceuticals, Emisphere Technologies, Corvidia Therapeutics, Ziylo, Calibrium, MB2 LLC, Xellia Pharmaceuticals, and more. Who are Novo Nordisk A/S's major shareholders? Top institutional shareholders of Novo Nordisk A/S include Saratoga Research & Investment Management (0.07%), Van ECK Associates Corp (0.02%), Corient Private Wealth LP (0.01%) and Nichols & Pratt Advisers LLP MA (0.01%). View institutional ownership trends. How do I buy shares of Novo Nordisk A/S? Shares of NVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Novo Nordisk A/S own? Based on aggregate information from My MarketBeat watchlists, some other companies that Novo Nordisk A/S investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), ServiceNow (NOW), Advanced Micro Devices (AMD), Salesforce (CRM) and Eli Lilly and Company (LLY). Company Calendar Last Earnings6/30/2026Record date for 8/25 Dividend8/17/2026Ex-Dividend for 8/25 Dividend8/17/2026Dividend Payable8/25/2026Today9/08/2026CMD 20269/21/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 NVO's financial health is in the Green zone, according to TradeSmith. NVO has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:NVO CIK353278 Webwww.novonordisk.com Phone(454) 444-8888Fax45-4449-0555Employees69,505Year Founded1923Price Target and Rating Average Price Target for Novo Nordisk A/S$64.94 High Price Target$175.00 Low Price Target$40.00 Potential Upside/Downside+43.8%Consensus RatingHold Rating Score (0-4)2.16 Research Coverage19 Analysts Profitability EPS (Trailing Twelve Months)$4.09 Trailing P/E Ratio11.04 Forward P/E Ratio13.09 P/E Growth1.56Net Income$15.51 billion Net Margins35.36% Pretax Margin47.66% Return on Equity61.20% Return on Assets21.49% Debt Debt-to-Equity Ratio0.59 Current Ratio0.79 Quick Ratio0.56 Sales & Book Value Annual Sales$46.80 billion Price / Sales4.31 Cash Flow$4.54 per share Price / Cash Flow9.94 Book Value$6.58 per share Price / Book6.86Miscellaneous Outstanding Shares4,465,000,000Free Float4,461,875,000Market Cap$201.60 billion OptionableOptionable Beta0.74 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NYSE:NVO) was last updated on 9/8/2026 by MarketBeat.com Staff. From Our PartnersThis looks like plywood. It's not.AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more e...Eagle Publishing | SponsoredWhat Is A Roth Conversion, And How Do I Set One Up?A Roth conversion moves money from a traditional IRA or employer plan into a Roth IRA, triggering income tax t...SmartAsset | SponsoredThis weekend trading strategy could change your MondaysEvery Monday, trader Tim Sykes opens his account to potential profits as high as $8,780, $9,177, even $16,000....Tim Sykes | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredMusk just exposed the crack in his empireSpaceX's IPO raised approximately $85.7 billion in gross proceeds. Days later, the company revealed its combin...The Oxford Club | SponsoredThey're not buying gold. They're buying this.Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...Behind the Markets | SponsoredSpaceX pays a 10X launch penaltySpaceX burns roughly $200,000 in fuel per Falcon 9 launch - about $20 million across 100 missions. One unde...Freedom Financial | SponsoredThe Closest Thing to a Virtual AI Monopoly Wall Street Is IgnoringA little-known company may be building the closest thing to a virtual AI monopoly that Wall Street has yet to ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novo Nordisk A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Novo Nordisk A/S With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NVO Stock Alerts